<DOC>
	<DOC>NCT03016650</DOC>
	<brief_summary>The investigators aimed to evaluate tramadol-sparing effect of intravenous (IV) ibuprofen in patients undergoing percutaneous nephrolithotomy (PCNL).</brief_summary>
	<brief_title>Opioid-sparing Effect of Intravenous Ibuprofen</brief_title>
	<detailed_description>Eighty patients who will undergoing PCNL are randomized to intravenous paracetamol (n=40) and intravenous ibuprofen (n=40) groups. Patients will receive 100 mL of physiologic saline with 1 g IV paracetamol or 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL in the paracetamol and ibuprofen groups, respectively. Patients in both groups will receive intravenous tramadol with patient controlled analgesia device (PCA). The visual analog scale (VAS) will used to evaluate pain intensity scores in the postoperative period. Total tramadol consumption, mean VAS score in the 1, 8 and 24 hours, demographic variables, operative variables, and side effects will record.</detailed_description>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Study include 80 patients of American Society of Anesthesiologists (ASA) physical status III aged between 1870 years who scheduled for percutaneous nephrolithotomy operation. chronic pain, psychiatric disease, renal dysfunction, allergy to nonsteroidal antiinflammatory drugs, history of drug addiction, pregnancy, inability to use a patient controlled analgesia (PCA) device.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Acetaminophen</keyword>
	<keyword>Ibuprofen</keyword>
</DOC>